Consolidation of remission aims to eliminate all detectable disease from the patient. In assessing the success of such attempts, the sensitivity of the method used to detect minimal residual disease is crucial. Unlike, many other haematological cancers, there is no characteristic chromosomal translocation to detect. Detection methods use either PCR to identify a unique tumour-associated sequence or flow cytometry to find an exclusive set of tumour antigens. The most sensitive assay uses PCR to detect a specific clonotypic sequence. This technique can ascertain 1 in 100 000 cells, but the IGHV gene needs to have been sequenced before treatment. Use of consensus primers to detect monoclonal immunoglobulin is much less sensitive, being only able to identify 1 in 1000 cells. Rawstron and colleagues  have developed a four-colour flow technique capable of detecting 1 in 50 000 cells, and this method has been refined further by an international group for use when anti-CD20 form part of the treatment strategy.
Remissions are traditionally consolidated with high-dose chemotherapy, sometimes with autologous stem-cell rescue. With this approach, a German research group could eliminate minimal residual disease and produce prolonged remissions in patients whose chronic lymphocytic leukaemia had mutated IGHV genes; however, for those with unmutated IGHV genes, molecular relapse was inevitable, and clinical relapse almost so, by 4 years' follow up. However, even this less-than-encouraging outcome might be better than what is achievable with conventional chemotherapy, according to findings of a comparison in matched historical controls. Moreover, stem-cell harvest is only possible in about two-thirds of patients with chronic lymphocytic leukaemia, and there is a worryingly high prevalence of secondary myelodysplastic syndrome. and 
Stem-cell allografts have been used in an attempt to capitalise on the graft-versus-leukaemia effect to eliminate minimal residual disease. In a largely elderly population, myeloablative conditioning leads to high treatment-related mortality of 40–50%.,  and  To combat this toxic effect, allotransplantation with reduced intensity conditioning, often followed by donor lymphocyte infusion, has become popular. Early results do not yet show an improvement in event-free survival compared with myeloablative transplants.,  and  In every series, a high frequency of chronic graft-versus-host disease is noted. Nevertheless, in patients with poor-risk prognostic markers, and especially those with 17p13 deletions, sustained remissions without molecular relapse are achievable.
Potentially less hazardous are attempts to consolidate remission with monoclonal antibodies. Alemtuzumab is especially suited because it can kill chronic lymphocytic leukaemia cells in a caspase-independent manner that is not inhibited by loss of TP53 protein  and is, therefore, able to eliminate chemotherapy-resistant cells. In a study of 91 previously treated patients, 44 of whom were refractory to purine analogues, complete remissions as defined by the US National Cancer Institute  were achieved in 32%. In these individuals, a four-colour flow technique for detection of minimal residual disease did not identify disease in 56%. Patients who became negative for minimal residual disease had significantly longer treatment-free and overall survival than those who did not.
In a prospective phase III study in Germany, patients were randomly allocated either no treatment or alemtuzumab 30 mg intravenously three times a week for 12 weeks, beginning a median of 67 days after the last dose of induction chemotherapy (fludarabine with or without cyclophosphamide). Although recruitment to this trial was halted at 21 patients because of severe infections in the alemtuzumab group, those allocated alemtuzumab had significantly longer progression-free survival than those assigned no treatment. Using a very sensitive PCR-based assay with sequence-specific primers to detect minimal residual disease, five of six patients tested became negative for minimal residual disease. Findings of a phase II study156 of alemtuzumab given in doses of 10 mg subcutaneously three times a week for 6 weeks, beginning not less than 8 weeks after discontinuation of fludarabine induction chemotherapy, proved that this regimen was safe and able to turn partial remissions into complete remissions. A PCR technique with consensus primers (a less sensitive method than that used in the phase III study) was used to detect minimal residual disease; patients with mutated IGHV genes were more likely to become negative for minimal residual disease than were those with unmutated IGHV genes. Reactivation of cytomegalovirus happened in 53% but was successfully treated with oral ganciclovir. 53% of patients successfully underwent autologous stem-cell transplantation, but no follow-up information is available. At present, immunological consolidation with alemtuzumab after chemotherapy seems safer than with allogeneic transplantation, but we await a comparison of efficacy.
138 A Noy, R Verma and M Glenn et al., Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol, Blood 97 (2001), pp. 1929–1936.
139 S Bottcher, M Ritgen and C Pott et al., Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation, Leukemia 18 (2004), pp. 1637–1645.
140 AC Rawstron, B Kennedy and PA Evans et al., Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy, Blood 98 (2001), pp. 29–35.
141 AC Rawstron, N Villamor and M Ritgen et al., International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia 21 (2007), pp. 956–964.
142 M Ritgen, A Lange and S Stilgenbauer et al., Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia, Blood 101 (2003), pp. 2049–2053.
143 P Dreger, S Stilgenbauer and A Benner et al., The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status, Blood 103 (2004), pp. 2850–2858.
144 DW Milligan, S Fernandes and R Dasgupta et al., Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses, Blood 105 (2005), pp. 397–404.
145 JG Gribben, D Zahrieh and K Stephans et al., Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia, Blood 106 (2005), pp. 4389–4396.
146 M Michallet, B Corront and D Hollard et al., Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases—report from the EBMTG, Bone Marrow Transplant 7 (1991), pp. 275–279.
147 S Paneesha and DW Milligan, Stem cell transplantation for chronic lymphocytic leukaemia, Br J Haematol 128 (2005), pp. 145–152.
148 P Dreger, R Brand and D Milligan et al., Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis, Leukemia 19 (2005), pp. 1029–1033.
149 JR Brown, HT Kim and S Li et al., Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia, Biol Blood Marrow Transplant 12 (2006), pp. 1056–1064.
150 J Delgado, K Thomson and N Russell et al., Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study, Blood 107 (2006),
151 D Caballero, JA Garcia-Marco and R Martino et al., Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-), Clin Cancer Res 11 (2005), pp. 7757–7763.
152 AP Mone, C Cheney and AL Banks et al., Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism, Leukemia 20 (2006), pp. 272–279.
153 G Lozanski, NA Heerema and IW Flinn et al., Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions, Blood 103 (2004), pp. 3278–3281.
154 P Moreton, B Kennedy and G Lucas et al., Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival, J Clin Oncol 23 (2005), pp. 2971–2979.
155 CM Wendtner, M Ritgen and CD Schweighofer et al., Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG), Leukemia 18 (2004), pp. 1093–1101.
156 M Montillo, A Tedeschi and S Miqueleiz et al., Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia, J Clin Oncol 24 (2006), pp. 2337–2342.